135 related articles for article (PubMed ID: 21956211)
1. Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice.
Ottewell PD; Brown HK; Jones M; Rogers TL; Cross SS; Brown NJ; Coleman RE; Holen I
Breast Cancer Res Treat; 2012 Jun; 133(2):523-36. PubMed ID: 21956211
[TBL] [Abstract][Full Text] [Related]
2. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.
Clyburn RD; Reid P; Evans CA; Lefley DV; Holen I
Cancer Chemother Pharmacol; 2010 Apr; 65(5):969-78. PubMed ID: 19730863
[TBL] [Abstract][Full Text] [Related]
3. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases.
Latimer P; Menchaca M; Snyder RM; Yu W; Gilbert BE; Sanders BG; Kline K
Exp Biol Med (Maywood); 2009 Oct; 234(10):1244-52. PubMed ID: 19657067
[TBL] [Abstract][Full Text] [Related]
4. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
[TBL] [Abstract][Full Text] [Related]
5. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.
Ottewell PD; Lefley DV; Cross SS; Evans CA; Coleman RE; Holen I
Int J Cancer; 2010 Jan; 126(2):522-32. PubMed ID: 19621384
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
[TBL] [Abstract][Full Text] [Related]
7. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
Duivenvoorden WC; Vukmirović-Popović S; Kalina M; Seidlitz E; Singh G
Br J Cancer; 2007 May; 96(10):1526-31. PubMed ID: 17437017
[TBL] [Abstract][Full Text] [Related]
8. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
9. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.
Marra M; Salzano G; Leonetti C; Porru M; Franco R; Zappavigna S; Liguori G; Botti G; Chieffi P; Lamberti M; Vitale G; Abbruzzese A; La Rotonda MI; De Rosa G; Caraglia M
Biotechnol Adv; 2012; 30(1):302-9. PubMed ID: 21741464
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
11. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
[TBL] [Abstract][Full Text] [Related]
12. Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study.
Zeng Q; Yang Z; Gao YJ; Yuan H; Cui K; Shi Y; Wang H; Huang X; Wong ST; Wang Y; Kesari S; Ji RR; Xu X
Eur J Cancer; 2010 Apr; 46(6):1132-43. PubMed ID: 20156674
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.
Odri GA; Dumoucel S; Picarda G; Battaglia S; Lamoureux F; Corradini N; Rousseau J; Tirode F; Laud K; Delattre O; Gouin F; Heymann D; Redini F
Cancer Res; 2010 Oct; 70(19):7610-9. PubMed ID: 20841471
[TBL] [Abstract][Full Text] [Related]
14. The backbone of progress--preclinical studies and innovations with zoledronic acid.
Green JR; Guenther A
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S3-S12. PubMed ID: 21353178
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models.
Luo KW; Ko CH; Yue GG; Lee MY; Siu WS; Lee JK; Shum WT; Fung KP; Leung PC; Li G; Evdokiou A; Lau CB
Cancer Lett; 2013 Oct; 339(1):42-8. PubMed ID: 23896464
[TBL] [Abstract][Full Text] [Related]
16. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH
Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538
[TBL] [Abstract][Full Text] [Related]
17. Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice.
Kim EJ; Hong JE; Eom SJ; Lee JY; Park JH
Breast Cancer Res Treat; 2011 Nov; 130(1):61-71. PubMed ID: 21170677
[TBL] [Abstract][Full Text] [Related]
18. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
Ottewell PD; Woodward JK; Lefley DV; Evans CA; Coleman RE; Holen I
Mol Cancer Ther; 2009 Oct; 8(10):2821-32. PubMed ID: 19789217
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
Lumsden AJ; Codde JP; Van der Meide PH; Gray BN
Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226
[TBL] [Abstract][Full Text] [Related]
20. In vivo anticancer synergy mechanism of doxorubicin and verapamil combination treatment is impaired in BALB/c mice with metastatic breast cancer.
McCarthy M; Auda G; Agrawal S; Taylor A; Backstrom Z; Mondal D; Moroz K; Dash S
Exp Mol Pathol; 2014 Aug; 97(1):6-15. PubMed ID: 24780744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
